Japan approves AstraZeneca’s Soliris for paediatric patients with gMG
August 24, 2023Medical Communications AstraZeneca, MHLW, Musculo-skeletal disorder, gMG, paediatric, soliris
AstraZeneca has announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Soliris (eculizumab) for the extended use …
FDA grants ODD to NXC-201 as multiple myeloma treatment
August 24, 2023Medical Communications FDA, Nexcella, ODD, Oncology, multiple myeloma
Nexcella has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to NXC-201 for …
GSK confirms positive results from shingles trial in China
August 23, 2023Research and Development GSK, Infections and infestations, clinical trials, shingles
GSK has announced positive results today from its first efficacy trial for Shingrix recombinant zoster vaccine (RZV) in China. These …
Daiichi Sankyo’s Enhertu approved in Japan as treatment for metastatic NSCLC
August 23, 2023Medical Communications Daiichi Sankyo, Enhertu, Japan's MHLW, NSCLC, Oncology, trastuzumab deruxtecan
Daiichi Sankyo has announced that Enhertu (trastuzumab deruxtecan) has been approved in Japan for the treatment of adult patients with …
Eli Lilly shares topline results from LIBRETTO-531 trial for Retevmo
August 23, 2023Research and Development Eli Lilly, Oncology, Retevmo, clinical trial, slpercatinib, thyroid cancer
Eli Lilly has announced topline results from the LIBRETTO-531 study assessing Retevmo (selpercatinib) as an initial treatment for patients with …
LEO Pharma to acquire Timber Pharmaceuticals for up to $36m
August 22, 2023Business Services Dermatology, LEO Pharma, Timber Pharmaceuticals, acquisition
Timber Pharmaceuticals has announced that it has entered a definitive agreement to be acquired by LEO Pharma, with a total …
Merck announces phase 3 LITESPARK-005 trial met primary endpoint
August 22, 2023Research and Development Merck, Oncology, Welireg, belzutifan, clinical trial, renal cell carcinoma
Merck (known as MSD outside of the US and Canada) has shared topline results from its phase 3 LITESPARK-005 trial, …
FDA approves Pfizer’s vaccine for the prevention of RSV in children
August 22, 2023Research and Development FDA, Paediatrics, Pfizer, RSV
On Monday, Pfizer announced that the US Food and Drug Administration (FDA) has approved Abrysvo for the prevention of respiratory …
Recce Pharmaceuticals shares data from phase 1/2 trial for burn wound infection
August 21, 2023Research and Development Recce Pharmaceuticals, Wound Healing, burn wounds, clinical trial, infection
Recce Pharmaceuticals has announced that it has completed its data analysis for its phase 1/2 clinical trial of Recce 327 …
Hutchmed announces phase 3 trial met primary endpoint for primary immune thrombocytopenia treatment
August 21, 2023Research and Development HUTCHMED, Haematology, clinical trial, sovleplenib, thrombocytopenia
Hutchmed has announced that its phase 3 trial ESLIM-01 trial assessing the use of sovleplenib has met its primary endpoint …
FDA approves first ever treatment for rare CHAPLE disease
August 21, 2023Research and Development CHAPLE disease, FDA, Rare Diseases, rare disease
The US Food and Drug Administration (FDA) has approved Regeneron’s Veopoz (pozelimab), a new treatment for CHAPLE disease for both …
Destiny Pharma appoints new CEO Chris Tovey
August 21, 2023Business Services CEO, Chris Tovey, Destiny Pharma, Infections and infestations
Destiny Pharma has announced the appointment of Chris Tovey, who will be replacing Dr Debra Barker as chief executive officer; …
FDA approves IMIDEX’s AI-powered device VisiRad XR
August 18, 2023Research and Development FDA, Radiology, pharma, radiology
The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug Administration (FDA) for its artificial …
AstraZeneca’s Forxiga approved in China for chronic heart failure treatment
August 18, 2023Medical Communications AstraZeneca, Cardiology, China, cardiovascular, heart failure
AstraZeneca has announced that Forxiga (dapagliflozin) has been approved in China to reduce the risk of cardiovascular death, hospitalisation for …
Iveric Bio’s marketing authorisation application for avacincaptad pegol accepted by EMA
August 18, 2023Medical Communications CHMP, EMA, Iveric Bio, MAA, Opthalmology
Astellas Pharma has announced that the European Medicines Agency (EMA) has accepted the marketing authorisation application (MAA) for avacincaptad pegol …
Dr Michael Lutz appointed as new chief executive officer of iotaSciences
August 18, 2023Business Services Dr Michael Lutz, Haematology, chief executive officer, iotasciences
The pharmaceutical discovery company iotaSciences has announced that it has appointed Dr Michael Lutz as its new chief executive officer. …
Foghorn Therapeutics appoints Alfonso Quintás-Cardama as new chief medical officer
August 18, 2023Business Services Alfonso Quintas-Cardama, Foghorn Therapeutics, Haematology, chief medical officer
The biotechnology company Foghorn Therapeutics has announced the addition of the new chief medical officer, Alfonso Quintás-Cardama, who will be …
Amicus Therapeutics’ Pompe disease treatment approved for use in UK
August 17, 2023Medical Communications Amicus Therapeutics, MHRA, NICE, Pompe disease, Rare Diseases
Amicus Therapeutics has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorisation …
FDA approved Ipsen’s Sohonos capsules for treatment of fibrodysplasia ossificans progressiva
August 17, 2023Medical Communications FDA, FOP, Musculo-skeletal disorder, Sohonos, ipsen
Ipsen has announced that the US Food and Drug Administration (FDA) has approved Sohonos (palovarotene) capsules as a retinoid indicated …
Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo
August 17, 2023Research and Development FDA, IND, Immunology, lupus nephritis, pharma
On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ Investigational New Drug (IND) application …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
